Grail, Inc. (NASDAQ:GRAL - Get Free Report) fell 4.1% during trading on Wednesday . The stock traded as low as $39.00 and last traded at $39.82. 1,246,067 shares traded hands during trading, an increase of 4% from the average session volume of 1,201,935 shares. The stock had previously closed at $41.54.
Wall Street Analyst Weigh In
A number of research firms have weighed in on GRAL. Wolfe Research started coverage on shares of Grail in a research report on Friday, November 15th. They set a "peer perform" rating on the stock. Morgan Stanley began coverage on shares of Grail in a report on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 price target on the stock.
View Our Latest Report on GRAL
Grail Trading Down 1.7 %
The stock has a 50 day moving average of $30.64 and a 200-day moving average of $20.87.
Grail (NASDAQ:GRAL - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($4.41) by $2.55. The business had revenue of $38.25 million for the quarter, compared to the consensus estimate of $35.33 million. On average, analysts anticipate that Grail, Inc. will post -15.15 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Grail
Several large investors have recently added to or reduced their stakes in GRAL. Crcm LP purchased a new position in shares of Grail during the fourth quarter worth approximately $65,061,000. Sessa Capital IM L.P. bought a new position in Grail in the fourth quarter worth approximately $53,550,000. Primecap Management Co. CA bought a new position in Grail in the fourth quarter worth approximately $37,118,000. Baker BROS. Advisors LP purchased a new position in Grail during the 4th quarter worth $29,098,000. Finally, Vanguard Group Inc. bought a new stake in Grail during the 4th quarter valued at $25,902,000.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
